Macquarie Group Ltd. Takes Position in Conatus Pharmaceuticals Inc (CNAT)
Macquarie Group Ltd. purchased a new stake in shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 60,100 shares of the biotechnology company’s stock, valued at approximately $330,000. Macquarie Group Ltd. owned about 0.20% of Conatus Pharmaceuticals as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in CNAT. Voya Investment Management LLC bought a new stake in shares of Conatus Pharmaceuticals in the second quarter valued at approximately $101,000. Bank of Montreal Can bought a new stake in shares of Conatus Pharmaceuticals in the second quarter valued at approximately $109,000. FNY Partners Fund LP boosted its position in shares of Conatus Pharmaceuticals by 98.0% in the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 9,800 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Conatus Pharmaceuticals in the second quarter valued at approximately $115,000. Finally, New York State Common Retirement Fund boosted its position in shares of Conatus Pharmaceuticals by 156.4% in the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 14,700 shares during the period. Institutional investors own 36.95% of the company’s stock.
CNAT has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Seaport Global Securities reissued a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Finally, Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $16.00.
Conatus Pharmaceuticals Inc (NASDAQ CNAT) opened at $4.27 on Friday. Conatus Pharmaceuticals Inc has a 12-month low of $1.88 and a 12-month high of $9.40. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.41.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.08). The firm had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same period last year, the business earned ($0.31) earnings per share. research analysts predict that Conatus Pharmaceuticals Inc will post -0.65 EPS for the current fiscal year.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.